Scantek Medical has found a Latin American distributor for a novel device that claims to detect early signs of breast disease by measuring differences in skin temperature between breast tissue. The Denville, NJ, company has licensed South American rights
Scantek Medical has found a Latin American distributor for a novel device that claims to detect early signs of breast disease by measuring differences in skin temperature between breast tissue. The Denville, NJ, company has licensed South American rights to its Breast Abnormality Indicator (BAI) to Sandell, a medical products distributor based in Montevideo, Uruguay.
BAI uses heat-sensitive pads that are placed on each breast to measure skin temperature, which may be higher in cancerous tissue due to its higher metabolic activity, according to Scantek. A temperature difference of 2F between mirror-image segments of the breasts indicates that a pathological condition may be present and that a patient should be sent on for mammography screening.
BAI is designed to be used as an adjunct to conventional mammography rather than as a replacement, according to the company. For example, it could be used to determine whether a woman under the age of 40 who might not normally receive regular mammography should be scheduled for a mammogram.
The Sandell agreement will complement a deal Scantek has with HumaScan of Cranford, NJ, which received marketing rights to BAI for the U.S. and Canada. HumaScan will sell the device as BreastAlert Differential Temperature Sensor (DTS) and plans to begin marketing the product in December. HumaScan has resolved issues that earlier this year forced the company to postpone the product's launch (SCAN 7/9/97). BAI has received 510(k) clearance from the Food and Drug Administration.
Scantek hopes to begin European sales of BAI early next year, and is lining up distribution partners for the product in that region, according to the company.
Emerging AI Algorithm Shows Promise for Abbreviated Breast MRI in Multicenter Study
April 25th 2025An artificial intelligence algorithm for dynamic contrast-enhanced breast MRI offered a 93.9 percent AUC for breast cancer detection, and a 92.3 percent sensitivity in BI-RADS 3 cases, according to new research presented at the Society for Breast Imaging (SBI) conference.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Can Abbreviated Breast MRI Have an Impact in Assessing Post-Neoadjuvant Chemotherapy Response?
April 24th 2025New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.
Clarius Mobile Health Unveils Anterior Knee Feature for Handheld Ultrasound
April 23rd 2025The T-Mode Anterior Knee feature reportedly offers a combination of automated segmentation and real-time conversion of grayscale ultrasound images into color-coded visuals that bolster understanding for novice ultrasound users.